Parkinson's disease (PD) is one of the major degenerative diseases for which there is no cure. There is therefore a pressing need to identify mechanisms implicated in PD pathogenesis that can be targeted for therapy. In this context, LRRK2, one of the major genetic determinants of sporadic and familial forms of MP, has emerged as a promising therapeutic target. Specifically, the importance of LRRK2 phosphorylation for its physiological and pathological functioning has recently become clear. Here, we will study the targeting of LRRK2 phosphorylation in PD models in drosophila, rodent neurons, rodent brains and in human cells. The validation of LRRK2 phosphorylation as a potential therapeutic target will open perspectives to develop modulators of phosphoregulators as candidate therapeutics for PD.